August 20, 2020 ― Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta? (ofatumumab, formerly OMB257) as an injection for subcutaneous use for the treatment of relapsing forms of ……
Aug. 4, 2020 -- MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce that the Europea……
July25, 2020 ? Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases……
July 7, 2020 ― Novartis today announced that the European Commission (EC) has approved Enerzair? Breezhaler? (QVM249; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance trea……
June 28, 2020-- Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by……
June 02, 2020 - AstraZeneca’s BRILINTA? (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of hear……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
